Saturday, February 02, 2008 9:00:06 AM
Not much new from the earlier conference. Some brief points (all 191 related):
1-Dr. Porter made a passing remark that could be taken that 191 BID dosing went well (something to the effect of better dosing then other PI's)
2-4th cohort may be done based on safety/tolerability.
3-Q2 still plan for starting combination trial
4-On track to release data from first 3 cohorts around end of quarter
5-Said Roche can and will design studies with all combinations of anti-virals in their portfolio. Hinted at doing this particular in the true non-responders.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM